Patients with idiopathic inflammatory myopathies suffer from worse self-reported PROMIS physical function after COVID-19 infection: an interview-based study from the MyoCite cohort

Kharbanda, Rajat; Ganatra, Keya; Abbasi, Maryam; Agarwal, Vikas; Gupta, Latika

doi:10.1007/s10067-022-06204-0

Cited by 8 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with myositis in general, especially those with underlying interstitial lung disease, may be particularly predisposed to symptomatic COVID infection and dyspnea on exertion [73].…”

Section: Covid-19 and Preexisting Myopathiesmentioning

confidence: 99%

COVID-19 associated myopathy

Aschman

Stenzel

2022

Current Opinion in Neurology

View full text Add to dashboard Cite

Purpose of reviewThe global spread of severe acute respiratory syndrome coronavirus 2 resulted in many cases of acute and postacute muscular symptoms. In this review, we try to decipher the potential underlying pathomechanisms and summarize the potential links between viral infection and muscle affection. Recent findingsDisregarding single case studies that do not allow safe conclusions due to the high number of infections, histopathological evidence of myositis has only been reported in deceased individuals with severe COVID-19. Postacute myalgia and weakness seem to occur in a subset of patients up to one year after initial infection, reminiscent of postinfectious syndromes (PIS) described in prior epidemics and pandemics of the past. Summary COVID-19 associated myopathy likely comprises different entities with heterogeneous pathomechanisms. Individual factors such as disease severity and duration, age, sex, constitutional susceptibilities, and preexisting conditions are important to consider when formulating a diagnosis. Persisting symptoms show overlapping features with PIS or postintensive care syndrome. In lack of strong evidence for a direct infection of myocytes, inflammatory myopathies associated with COVID-19 are presumably immune-mediated. Differential diagnosis of rheumatological and nonmuscular neurological origin coinciding with the infection need to be considered, due to the extremely high numbers of newly occurring infections the last 2 years.

show abstract

“…Patients with myositis in general, especially those with underlying interstitial lung disease, may be particularly predisposed to symptomatic COVID infection and dyspnea on exertion [73].…”

Section: Covid-19 and Preexisting Myopathiesmentioning

confidence: 99%

COVID-19 associated myopathy

Aschman

Stenzel

2022

Current Opinion in Neurology

View full text Add to dashboard Cite

show abstract

“…with associated autoimmune comorbidities, as identified by the COVAD group in previous publications, both being avenues for further research. 13,14 One limitation of our study is the self-reported nature of the In conclusion, our study affirms the importance of monitoring for disease flares post-COVID-19 infection in vulnerable AIRD patients.…”

mentioning

confidence: 61%

Flares of autoimmune rheumatic disease following COVID‐19 infection: Observations from the COVAD study

Sandhu,

Ravichandraan,

Nune

et al. 2023

Int J of Rheum Dis

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic has significantly impacted the health of individuals with autoimmune rheumatic diseases (AIRDs), who being immunologically vulnerable, are at an increased risk of complications following a COVID-19 infection. 1,2 This can be attributed to the derangement of the interferon axis in both autoimmune diseases and COVID-19 infection. Particularly, type I interferons have been indicated in the pathogenesis of autoimmune diseases 3 and in the generation of an immune response to a COVID-19 infection. 4,5 The similar pathogenesis puts patients with AIRDs at an increased risk for disease exacerbations. Although there is a wealth of data concerning new onset phenomena following a COVID-19 infection, there remains a scarcity of information regarding the characteristics and risk factors associated with disease flares in patients with AIRDs subsequent to a COVID-19 infection. 6 The COVID-19 vaccination in autoimmune diseases (COVAD) study is an international collaborative study involving 167 collaborators in 110 countries designed to explore the different facets of COVID-19 infection, vaccination, and disease activity in individuals with AIRDs. 7-9 The COVAD database is an ideal cohort for this study due to its extensive geographical coverage including under-represented regions, and its use of validated tools. Using a standardized and validated self-reported questionnaire, the COVAD study collected data regarding demographics, vaccine types, medications, and comorbid conditions in patients with AIRDs and healthy controls. Binary logistic regression (BLR) analyses were performed with adjustment for age, gender, ethnicity, vaccine type, immunosuppressive medications, comorbidities, COVID-19 antibody status, and clinical features during previous COVID-19 infection, stratified by country of residence (detailed methods in Supplementary File S1). Medians and interquartile ranges (IQRs) were used to summarize continuous data and Chisquared (χ 2 ) and Mann-Whitney U tests were used to compare AIRD patients with flares to those without flares for categorical and continuous variables, respectively. Finally, physical and mental health, fatigue, and pain were assessed using the PROMIS PF10 scores.

show abstract

“…Some papers have used the threshold of a two- to six-point difference in scores to represent a clinically meaningful change [ 34 ]. A handful of studies have measured PROMIS scores in COVID-19 populations, but these early studies are varied based on the population studied, the duration, and the specific focus area [ 23 , 33 , 35 , 36 ]. One study that examined changes in PROMIS-10 collected during ambulatory care visits before and after COVID-19 infection found one-quarter of patients had worsening PROMIS-10 Global T-scores over time in the months after their COVID-19 diagnoses [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Patient-Reported Outcomes for Fully Vaccinated COVID-19 Patients Over 6 Weeks: The Experiences of Clinical Breakthrough Cases

Vartanian

Fish

Gronowski

et al. 2022

Patient

View full text Add to dashboard Cite

Background While coronavirus disease 2019 (COVID-19) vaccines have high rates of efficacy, fully vaccinated individuals can become infected with COVID-19. Among this population, symptoms tend to be less severe and shorter lasting. Less is known about how vaccinated individuals who contract COVID-19 experience the disease through patient-reported outcomes (PROs) and how this changes over time. Objective The aim of this study was to describe the physical, mental, and social health PROs for fully vaccinated individuals who contracted COVID-19 over a 6-week period. Design Prospective design using the Patient-Reported Outcomes Measurement Information System short-form (PROMIS-10) collected through a mobile application-based platform. Participant 1114 fully vaccinated patients who tested positive for COVID-19 at a large US health system and engaged with the study on or after 1 March 2021 and reported onset of illness prior to 1 November 2021. Main Measures Global physical and mental health PROMIS-10 T-scores for the 6-week period, component PROMIS-10 questions for the 6-week period, and component PROMIS-10 questions restricted to a subset of participants for the first month to measure individual recovery were analyzed. Key Results Mean global physical and mental health T-scores increased over time and remained within one standard deviation of the population mean. At baseline, at least 40% of participants reported good health for all component questions except Fatigue (25%), and the proportion reporting good health increased over time for all questions, with the largest improvements in Fatigue (25.5 to 67.5%), Pain (59.1 to 82.8%), and Emotional Problems (42.3 to 62.5%). Over the first month, the greatest positive changes in individual recovery were observed for Fatigue (65.0%), Pain (53.0%), and Emotional Problems (41.1%); at least 30% of respondents reported no change in at least one category, and the greatest decreases were for Usual Social Activities (23.9%), Social Satisfaction (23.2%), and Mental Health (21.8%). Conclusions This study provides an important step towards better understanding the impact of ‘breakthrough’ COVID-19 infections on clinically engaged, fully vaccinated patients’ physical and mental health to improve support for their treatment and recovery. Supplementary Information The online version contains supplementary material available at 10.1007/s40271-022-00605-8.

show abstract

Patients with idiopathic inflammatory myopathies suffer from worse self-reported PROMIS physical function after COVID-19 infection: an interview-based study from the MyoCite cohort

Cited by 8 publications

References 6 publications

COVID-19 associated myopathy

COVID-19 associated myopathy

Flares of autoimmune rheumatic disease following COVID‐19 infection: Observations from the COVAD study

Patient-Reported Outcomes for Fully Vaccinated COVID-19 Patients Over 6 Weeks: The Experiences of Clinical Breakthrough Cases

Contact Info

Product

Resources

About